Literature DB >> 32267531

COVID-19 Obstetrics Task Force, Lombardy, Italy: Executive management summary and short report of outcome.

Enrico M Ferrazzi1,2, Luigi Frigerio3, Irene Cetin4,5, Patrizia Vergani6, Arsenio Spinillo7, Federico Prefumo8, Edda Pellegrini9, Gianluigi Gargantini9.   

Abstract

From February 24, 2020, a COVID-19 obstetric task force was structured to deliver management recommendations for obstetric care. From March 1, 2020, six COVID-19 hubs and their spokes were designated. An interim analysis of cases occurring in or transferred to these hubs was performed on March 20, 2020 and recommendations were released on March 24, 2020. The vision of this strict organization was to centralize patients in high-risk maternity centers in order to concentrate human resources and personal protective equipment (PPE), dedicate protected areas of these major hospitals, and centralize clinical multidisciplinary experience with this disease. All maternity hospitals were informed to provide a protected labor and delivery room for nontransferable patients in advanced labor. A pre-triage based on temperature and 14 other items was developed in order to screen suspected patients in all hospitals to be tested with nasopharyngeal swabs. Obstetric outpatient facilities were instructed to maintain scheduled pregnancy screening as per Italian guidelines, and to provide pre-triage screening and surgical masks for personnel and patients for pre-triage-negative patients. Forty-two cases were recorded in the first 20 days of hub and spoke organization. The clinical presentation was interstitial pneumonia in 20 women. Of these, seven required respiratory support and eventually recovered. Two premature labors occurred.
© 2020 International Federation of Gynecology and Obstetrics.

Entities:  

Keywords:  COVID-19; SARS-CoV-2; pregnancy

Mesh:

Year:  2020        PMID: 32267531      PMCID: PMC9087792          DOI: 10.1002/ijgo.13162

Source DB:  PubMed          Journal:  Int J Gynaecol Obstet        ISSN: 0020-7292            Impact factor:   4.447


The Regional Health Authority of Lombardy, Italy, instructed the COVID‐19 Obstetrics Task Force (OTF) to develop recommendations by March 24, 2020, for the management of pregnant women during the coronavirus disease 2019 (COVID‐19) pandemic and to designate a dedicated network of maternity hubs for COVID‐19‐positive patients. Since pregnancy is a time‐dependent condition in terms of health care, the OTF recommended that all outpatient facilities should continue to provide the same level of care as required by pregnant women. Outpatient areas should have a pre‐triage area where each patient's temperature and 14 specific items can be checked to identify possible suspected cases based on symptoms, and possible contacts with positive patients. Each outpatient facility should have a dedicated area where pregnant patients with suspected COVID‐19 can be tested safely by healthcare personnel wearing personal protective equipment (PPE); PPE should also be worn during consultation or ultrasound with such patients. Patients with suspected COVID‐19 must self‐isolate until the test results are known, with PPE being provided by the hospital for home self‐quarantine. The OTF designated a network of six COVID‐19 maternity hubs along with their connecting spokes. The aim of the reorganization was to concentrate COVID‐19 cases, procedures and medical devices, and research into a geographic ring of six referral hospitals with maternal–fetal medicine and neonatal intensive care unit (ICU) facilities. This network was activated on March 1, 2020. By that time, progressive lockdown measures were in force. In a liberal country, imposing measures suddenly was deemed difficult; however, not imposing strict lockdown or strict measures of personal restriction of mobility and individual distancing sooner was a mistake—as replicated in other countries.1 The media played a key role in helping to disseminate the information surrounding the lockdown restrictions. All maternity centers should perform a pre‐triage based on temperature and a specific questionnaire before entering the common emergency room in order to identify as far as possible suspected cases, who should receive nasopharyngeal swabs and be admitted to isolated facilities or transferred as suspected positives to designated maternity hubs. Maternity hubs should have a 24‐hour pre‐triage policy at all centers, plus separate emergency room facilities for pregnant women (transferred from other hospitals) with suspected or confirmed COVID‐19, separate labor and delivery suites, and a separate postpartum ward. Healthcare providers should wear appropriate PPE for confirmed and suspected cases in all areas. All connecting network hospitals (n=50) should be able to organize a protected vaginal or cesarean delivery for a woman in advanced labor who cannot be transferred. This means appropriate PPE must be available, and one dedicated labor and delivery or operating room must be made available for this emergency situation. The first interim analysis was carried out during the period March 1–20, 2020, deriving data from a dedicated database shared by all maternity hubs and summarized in the present article. A total of 42 pregnant women with confirmed COVID‐19 delivered during this time period.2 These cases represent approximately 0.6% of the expected 7000 deliveries in the same region over the same time period. The clinical presentation was interstitial pneumonia in 20 (48%) women; 7 (35%) of these required continuous positive airway pressure (cPAP) or were admitted to the ICU. All did well to recover in a shorter period of time compared with the typical 10‐15 days required to overcome the critical phase of SARS‐CoV‐2 pneumonia. A total of 18 (43%) women were delivered by cesarean, and 24 (57%) delivered vaginally. Only two patients had a spontaneous premature delivery. Since this report was collected a few more cases requiring major respiratory support have been recorded by COVID‐19 hubs, presenting with dyspnea that required immediate treatment, both during pregnancy and postpartum. These few but critical cases underline the benefits of the policy of centralization, as patients were transferred to the designated maternity hubs. On the other hand, in women who develop COVID‐19 during pregnancy, the symptoms tend to be mild or moderate,3 possibly as a result of the combined effects of gender, young age, and immune status of pregnancy; this suggests that, in an area of high prevalence of infection, more women may be positive but asymptomatic. Therefore, the rules of protection for healthcare providers working in labor and delivery have been updated to cover ALL laboring women: During labor the midwife and laboring woman wear surgical masks. During the second stage of labor the midwife wears appropriate PPE. A woman's partner is permitted to attend during labor and delivery but is not permitted on the postpartum ward. Regarding breastfeeding: ALL women breastfeed while wearing a surgical mask. COVID‐19‐positive mothers with mild or no symptoms can breastfeed. COVID‐19‐positive and symptomatic mothers are separated from their newborns, and women can use pumps to express breast milk. The OTF typically holds a video conference call every 15 days to discuss possible upgrading of the recommendations.

AUTHOR CONTRIBUTIONS

EMF, IC, PV, EP, and GG contributed as members of the COVID‐19 Obstetric Task Force. LF, EMF, IC, PV, AS and FP contributed to the interim analysis. GG and EP chaired the task force on behalf of the Regional Health Care Authority.

CONFLICTS OF INTEREST

The authors have no conflicts of interest.
  3 in total

1.  Vaginal delivery in SARS-CoV-2-infected pregnant women in Northern Italy: a retrospective analysis.

Authors:  E Ferrazzi; L Frigerio; V Savasi; P Vergani; F Prefumo; S Barresi; S Bianchi; E Ciriello; F Facchinetti; M T Gervasi; E Iurlaro; A Kustermann; G Mangili; F Mosca; L Patanè; D Spazzini; A Spinillo; G Trojano; M Vignali; A Villa; G V Zuccotti; F Parazzini; I Cetin
Journal:  BJOG       Date:  2020-05-28       Impact factor: 6.531

2.  Offline: COVID-19 and the NHS-"a national scandal".

Authors:  Richard Horton
Journal:  Lancet       Date:  2020-03-28       Impact factor: 79.321

3.  Global interim guidance on coronavirus disease 2019 (COVID-19) during pregnancy and puerperium from FIGO and allied partners: Information for healthcare professionals.

Authors:  Liona C Poon; Huixia Yang; Anil Kapur; Nir Melamed; Blami Dao; Hema Divakar; H David McIntyre; Anne B Kihara; Diogo Ayres-de-Campos; Enrico M Ferrazzi; Gian Carlo Di Renzo; Moshe Hod
Journal:  Int J Gynaecol Obstet       Date:  2020-04-28       Impact factor: 4.447

  3 in total
  33 in total

Review 1.  The Impact of the SARS-CoV-2 Pandemic on Healthcare Provision in Italy to non-COVID Patients: a Systematic Review.

Authors:  Gianmarco Lugli; Matteo Maria Ottaviani; Annarita Botta; Guido Ascione; Alessandro Bruschi; Federico Cagnazzo; Lorenzo Zammarchi; Paola Romagnani; Tommaso Portaluri
Journal:  Mediterr J Hematol Infect Dis       Date:  2022-01-01       Impact factor: 2.576

Review 2.  Coronavirus Disease 2019 in Pregnancy and Outcomes Among Pregnant Women and Neonates: A Literature Review.

Authors:  Elyse G Mark; Samuel McAleese; W Christopher Golden; Maureen M Gilmore; Anna Sick-Samuels; Melanie S Curless; Lawrence M Nogee; Aaron M Milstone; Julia Johnson
Journal:  Pediatr Infect Dis J       Date:  2021-05-01       Impact factor: 2.129

Review 3.  Practical Recommendations for the Management of Patients with ITP During the COVID-19 Pandemic.

Authors:  Francesco Rodeghiero; Silvia Cantoni; Giuseppe Carli; Monica Carpenedo; Valentina Carrai; Federico Chiurazzi; Valerio De Stefano; Cristina Santoro; Sergio Siragusa; Francesco Zaja; Nicola Vianelli
Journal:  Mediterr J Hematol Infect Dis       Date:  2021-05-01       Impact factor: 2.576

4.  A pre-systematic review on the use of masks as a protection material for SARS-COV-2 during the COVID-19 pandemic.

Authors:  Carla Pires
Journal:  Int J Clin Pract       Date:  2021-04-27       Impact factor: 3.149

Review 5.  COVID-19 and pregnancy: A scoping review on pregnancy characteristics and outcomes.

Authors:  Karoline Faria de Oliveira; Jacqueline Faria de Oliveira; Monika Wernet; Marina Carvalho Paschoini; Mariana Torreglosa Ruiz
Journal:  Int J Nurs Pract       Date:  2021-05-16       Impact factor: 2.226

6.  COVID-19 guidelines for pregnant women and new mothers: A systematic evidence review.

Authors:  Madeline A DiLorenzo; Sarah K O'Connor; Caroline Ezekwesili; Spoorthi Sampath; Molly Zhao; Christina Yarrington; Cassandra Pierre
Journal:  Int J Gynaecol Obstet       Date:  2021-03-29       Impact factor: 4.447

7.  Evaluating the effects of the COVID-19 pandemic on the physical and mental well-being of obstetricians and gynecologists in Turkey.

Authors:  Pınar Yalçın Bahat; Merve Aldıkaçtıoğlu Talmaç; Ayşegül Bestel; Nura F Topbas Selcuki; Ozan Karadeniz; Ibrahim Polat
Journal:  Int J Gynaecol Obstet       Date:  2020-08-11       Impact factor: 4.447

Review 8.  Coronavirus Disease 2019 in Pregnancy: A Clinical Management Protocol and Considerations for Practice.

Authors:  Marta López; Anna Gonce; Eva Meler; Ana Plaza; Sandra Hernández; Raigam J Martinez-Portilla; Teresa Cobo; Felipe García; Maria Dolores Gómez Roig; Eduard Gratacós; Montse Palacio; Francesc Figueras
Journal:  Fetal Diagn Ther       Date:  2020-06-12       Impact factor: 2.587

Review 9.  Clinical update on COVID-19 in pregnancy: A review article.

Authors:  Gillian A Ryan; Nikhil C Purandare; Fionnuala M McAuliffe; Moshe Hod; Chittaranjan N Purandare
Journal:  J Obstet Gynaecol Res       Date:  2020-06-04       Impact factor: 1.697

10.  Association of ABO and Rh blood groups with obstetric outcomes in SARS-CoV-2 infected pregnancies: A prospective study with a multivariate analysis.

Authors:  José Antonio Sainz Bueno; Lucas Cerrillos González; Alejandra Abascal-Saiz; María Victoria Rodríguez Gallego; Rocío López Pérez; Ana María Fernández Alonso; Maria Luisa de la Cruz Conty; Rubén Alonso Saiz; Magdalena Molina Oller; Amparo Santamaría Ortiz; Óscar Martínez-Pérez
Journal:  Eur J Obstet Gynecol Reprod Biol       Date:  2021-07-07       Impact factor: 2.435

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.